302 related articles for article (PubMed ID: 15802273)
1. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.
Williams TM; Hassan GS; Li J; Cohen AW; Medina F; Frank PG; Pestell RG; Di Vizio D; Loda M; Lisanti MP
J Biol Chem; 2005 Jul; 280(26):25134-45. PubMed ID: 15802273
[TBL] [Abstract][Full Text] [Related]
2. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.
Williams TM; Medina F; Badano I; Hazan RB; Hutchinson J; Muller WJ; Chopra NG; Scherer PE; Pestell RG; Lisanti MP
J Biol Chem; 2004 Dec; 279(49):51630-46. PubMed ID: 15355971
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression.
Di Vizio D; Sotgia F; Williams TM; Hassan GS; Capozza F; Frank PG; Pestell RG; Loda M; Freeman MR; Lisanti MP
Cancer Biol Ther; 2007 Aug; 6(8):1263-8. PubMed ID: 17786030
[TBL] [Abstract][Full Text] [Related]
4. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation.
Capozza F; Williams TM; Schubert W; McClain S; Bouzahzah B; Sotgia F; Lisanti MP
Am J Pathol; 2003 Jun; 162(6):2029-39. PubMed ID: 12759258
[TBL] [Abstract][Full Text] [Related]
5. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia.
Williams TM; Lee H; Cheung MW; Cohen AW; Razani B; Iyengar P; Scherer PE; Pestell RG; Lisanti MP
J Biol Chem; 2004 Jun; 279(23):24745-56. PubMed ID: 15044451
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells.
Li L; Yang G; Ebara S; Satoh T; Nasu Y; Timme TL; Ren C; Wang J; Tahir SA; Thompson TC
Cancer Res; 2001 Jun; 61(11):4386-92. PubMed ID: 11389065
[TBL] [Abstract][Full Text] [Related]
7. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
[TBL] [Abstract][Full Text] [Related]
8. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice.
Williams TM; Cheung MW; Park DS; Razani B; Cohen AW; Muller WJ; Di Vizio D; Chopra NG; Pestell RG; Lisanti MP
Mol Biol Cell; 2003 Mar; 14(3):1027-42. PubMed ID: 12631721
[TBL] [Abstract][Full Text] [Related]
9. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 in oncogenic transformation, cancer, and metastasis.
Williams TM; Lisanti MP
Am J Physiol Cell Physiol; 2005 Mar; 288(3):C494-506. PubMed ID: 15692148
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression.
Watanabe M; Yang G; Cao G; Tahir SA; Naruishi K; Tabata K; Fattah EA; Rajagopalan K; Timme TL; Park S; Kurosaka S; Edamura K; Tanimoto R; Demayo FJ; Goltsov AA; Thompson TC
Mol Cancer Res; 2009 Sep; 7(9):1446-55. PubMed ID: 19737975
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
13. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.
Ayala G; Morello M; Frolov A; You S; Li R; Rosati F; Bartolucci G; Danza G; Adam RM; Thompson TC; Lisanti MP; Freeman MR; Vizio DD
J Pathol; 2013 Sep; 231(1):77-87. PubMed ID: 23729330
[TBL] [Abstract][Full Text] [Related]
14. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
16. Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma.
Patel SJ; Molinolo AA; Gutkind S; Crawford NP
PLoS One; 2013; 8(4):e61848. PubMed ID: 23620793
[TBL] [Abstract][Full Text] [Related]
17. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model.
Cho HJ; Park SY; Kim EJ; Kim JK; Park JH
Mol Carcinog; 2011 Feb; 50(2):100-12. PubMed ID: 21229607
[TBL] [Abstract][Full Text] [Related]
18. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
[TBL] [Abstract][Full Text] [Related]
19. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of the caveolin-1 gene promoter in prostate cancer.
Cui J; Rohr LR; Swanson G; Speights VO; Maxwell T; Brothman AR
Prostate; 2001 Feb; 46(3):249-56. PubMed ID: 11170154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
